brimonidine tartrate / Generic mfg. - LARVOL DELTA

Exploring New Dimensions in Longitudinal Rosacea Management. (PubMed, Dermatol Ther (Heidelb)) - "Deepening the understanding of the condition as a chronic, yet eminently manageable one, will help empower patients with rosacea and their dermatologists alike. The REACH GSC project was initiated and funded by Galderma."

Journal • Review • Dermatology • Inflammation • Rosacea

Pharmacovigilance analysis of vision disorders relating to brimonidine treatment and mechanism study using network toxicology and molecular docking. (PubMed, Sci Rep) - No abstract available

Adverse events • Journal • Retinal Disorders

Evaluation of contamination in preservative-free multi-dose Brimonidine eye drops: a comparative study. (PubMed, Jpn J Ophthalmol) - "PF-MDB bottle technology effectively prevents microbial contamination in the bottle without preservatives. However, due to the lack of a preservative, there is increased bacterial and fungal growth associated with contamination on the cap, as well as in the first and second drops, compared to P-MDB."

Journal • Glaucoma • Ophthalmology

Engineered Multifunctional Drug-Loaded Dendrimer Nanoparticles for Glaucoma: Triple Mechanism via Antioxidant Activity, Iron Chelation, and Enhanced Ocular Transport. (PubMed, Biomacromolecules) - "In this study, we developed multifunctional nanoparticles based on polyamidoamine (PAMAM) dendrimers functionalized with caffeic acid (CA) and poly(ethylene glycol) maleimide (PEGM) for the topical delivery of hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX). Both PAMAM-CA and PAMAM-CA-PEGM nanoparticles exhibited concentration-dependent antioxidant activity comparable to that of CA. These findings suggest the potential of this multifunctional dendrimer-based nanoparticle system as an innovative strategy for glaucoma medication."

Journal • Glaucoma • Ophthalmology

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov) - P4 | N=35 | Recruiting | Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Brimonidine Allergy Presenting as Corneal Subepithelial Infiltrates. (PubMed, Korean J Ophthalmol) - No abstract available

Journal • Allergy • Immunology

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: Westlake Eye Specialists | Trial completion date: Dec 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Sep 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana. (PubMed, PLOS Glob Public Health) - "Latanoprost (32.2%), timolol (23.7%), travoprost (17.6%), and brimonidine (10.2%) were the medications most frequently associated with these reactions. These findings highlight that although OADRs are common in glaucoma management, optometrists in Ghana often lack standardized protocols and report low confidence in handling such cases. Targeted professional development and refresher training are needed to strengthen OADRs recognition, reporting, and management, ultimately improving patient eye care."

Journal • Dry Eye Disease • Glaucoma • Ophthalmology

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov) - P4 | N=35 | Not yet recruiting | Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

New P4 trial • Glaucoma • Ophthalmology

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Tulane University | Trial completion date: Jun 2035 ➔ Jun 2036 | Trial primary completion date: Jun 2030 ➔ Jun 2031

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Westlake Eye Specialists | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults. (PubMed, Ophthalmol Ther) - P3 | "BTOS-PF 0.025% was non-inferior to LUMIFY 0.025% in reducing ocular redness in adults, was well-tolerated, and offers an alternative topical solution, without loss of efficacy or compromised safety, for patients who prefer a preservative-free formulation or are at increased risk of OSD."

Clinical • Journal • Infectious Disease • Ocular Infections • Ophthalmology

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution (clinicaltrials.gov) - P3 | N=512 | Completed | Sponsor: Bausch & Lomb Incorporated | Phase classification: P ➔ P3

Phase classification • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics

Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. (PubMed, PLoS One) - "Alphagan-P can reduce up to 0.5D of post-LASIK residual myopia in roughly 50% of subjects. This treatment might be recommended to fine-tune outcomes for low residual myopia."

Journal • Retrospective data • Ophthalmology

Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion. (PubMed, Am J Ophthalmol Case Rep) - "Collagen and silicone punctal plugs were placed and the patient was started on preservative free artificial tears, topical loteprednol 0.5 %, later replaced with topical prednisolone acetate 1 % drops, and brimonidine 0.2 % in both eyes. Ocular symptoms and exam findings waxed and waned with continued infusions of the ADC. This case reports an incidence of corneal pseudomicrocysts associated with TORL-1-23 treatment, which should be recognized as a potential adverse effect of this novel therapy."

Journal • Oncology • Ophthalmology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Pain • Solid Tumor • CLDN6

Pupillometry changes following ocular administration of brimonidine in patients experiencing acute migraine attack. (PubMed, Medicine (Baltimore)) - "The study findings suggest that patients experiencing acute migraine attacks demonstrate shorter pupillary constriction latencies, indicating the presence of accompanying sympathetic hypoactivity in migraine patients. Latency prolongation after brimonidine suggests sympathetic hyperfunction secondary to chronic sympathetic hypofunction in migraine patients. Brimonidine, with its ability to cross the blood-brain barrier, may provide pain relief through a mechanism similar to that of latency prolongation. This study sheds light on the potential role of brimonidine tartrate in the management of acute migraine attacks, and highlights its effects on pupillometric parameters, thereby contributing to our understanding of migraine pathophysiology and potential treatment avenues."

Clinical • Journal • CNS Disorders • Migraine • Pain

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness (clinicaltrials.gov) - P3 | N=578 | Completed | Sponsor: Bausch & Lomb Incorporated | Recruiting ➔ Completed

Trial completion • Ophthalmology

Effects of taurine, brimonidine and betaxolol on oscillation modulation and stimulation efficiency in degenerated rd10 mouse retinas. (PubMed, Sci Rep) - "The drugs tested appear to be promising therapeutic candidates for improving the residual function of RGCs. They will be further investigated and combined with other RP treatments, such as retinal prostheses, in the future."

Journal • Preclinical • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis. (PubMed, Actas Dermosifiliogr) - "Minocycline turned out to be effective improving the symptoms of rosacea. Brimonidine and oxymetazoline both have significant effects on reducing facial redness."

Journal • Retrospective data • Review • Dermatology • Rosacea

Effect of low-dose brimonidine on scotopic mydriasis: a potential approach to dysphotopsia management (SOE 2025) - "Low dose brimonidine demonstrated a tendency to reduce mydriatic response under scotopic conditions. This effect suggests its potential clinical utility to manage uneventful postoperative dysphotopsia. A possible correlation between higher order aberrations and scotopic pupillary diameter could reinforce our results."

Ophthalmology

A Randomized, Double-Blind, Placebo-Controlled, Self-Controlled Study on the Analgesic-Enhancing Effect of Brimonidine Tartrate Eye Drops as an Adjunct to Compound Lidocaine Cream (ChiCTR) - P1 | N=66 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University

New P1 trial • Pain

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness (clinicaltrials.gov) - P3 | N=554 | Recruiting | Sponsor: Bausch & Lomb Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

Incidence of and factors associated with brimonidine allergy. (PubMed, PLoS One) - "Approximately 5.5% of brimonidine users developed brimonidine allergy, which typically manifested at 32 weeks. Concurrent artificial tear and tafluprost use increased brimonidine allergy risk, whereas topical steroids' concomitant use reduced the risk."

Journal • Retrospective data • Allergy • Immunology

Brimonidine Eye Drops in the Prevention of Myopia Progression (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

New P2 trial • Ophthalmology

Usefulness of Measuring Corneal Stiffness in Predicting the Reduction of Intraocular Pressure With Microhook Ab Interno Trabeculotomy. (PubMed, Transl Vis Sci Technol) - "ORA and Corvis ST measurements suggested that stiff cornea was a risk factor for high postoperative GAT-IOP after TLO, in addition to preoperative high Hb, high CRP, and the use of brimonidine tartrate. Stiff cornea is a risk factor for high postoperative intraocular pressure after trabeculotomy."

Journal • Glaucoma • Ophthalmology • CRP